Savara (SVRA) Amortizatization of Intangibles (2012 - 2026)
Savara (SVRA) posted quarterly Amortizatization of Intangibles of $565000.0 for Q1 2026, down 50.83% year-over-year from $1.1 million in Q1 2025, and up 15.31% quarter-over-quarter from $490000.0 in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Savara (SVRA) has reported Amortizatization of Intangibles for 8 consecutive years, with $565000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 50.83% year-over-year to $565000.0; the TTM figure through Mar 2026 stood at $2.3 million (down 56.29% YoY), while the FY2025 annual figure was $2.9 million, down 47.34% from the prior year.
- Amortizatization of Intangibles rose to $565000.0 in Q1 2026 per SVRA's latest filing, from $490000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.6 million in Q4 2023 and bottomed at -$267000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $810705.9 across 5 years, with a median of $913000.0 in 2023.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 2572.13% — and 2025, when it slumped 71.16%.
- Savara's Amortizatization of Intangibles stood at $357000.0 in 2022, then soared by 359.1% to $1.6 million in 2023, then slipped by 10.31% to $1.5 million in 2024, then slumped by 66.67% to $490000.0 in 2025, then increased by 15.31% to $565000.0 in 2026.
- Business Quant data shows SVRA's Amortizatization of Intangibles at $565000.0 in Q1 2026, $490000.0 in Q4 2025, and $426000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | 422,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 422,000.00 |
| Mar 31, 2026 | 565,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Sep 30, 2025 | 426,000.00 |
| Jun 30, 2025 | 801,000.00 |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 913,000.00 |
| Mar 31, 2023 | 924,000.00 |
| Dec 31, 2022 | 568,000.00 |
| Sep 30, 2022 | -61,000.00 |
| Jun 30, 2022 | -104,000.00 |
| Mar 31, 2022 | -267,000.00 |
| Dec 31, 2021 | -435,000.00 |
| Sep 30, 2021 | -501,000.00 |